eligibility_summary
Eligibility: FDG-avid R/R classical HL or CD30+ (≥1%) R/R PTCL (PTCL-NOS, AITL, ALCL ALK±). HL: ≥2 prior lines incl combo chemo, brentuximab, PD-1, PTCL: ≥1 combo, ALCL: brentuximab or intolerant. Prior ASCT ≥3 mo, allo-SCT ≥1 yr without GVHD, CAR-T ≥6 mo. Consent required. Exclude: active CNS disease, prior AFM13/CBNK, solid organ transplant, IL-2–exacerbated autoimmunity, therapeutic mAb/immunosuppression, active HBV/HCV/HIV, other cancer <2 yrs, active GVHD/CNS dysfunction.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05883449 tests AFM13 plus AB‑101 with lymphodepletion (cyclophosphamide, fludarabine) and IL‑2 in R/R classical Hodgkin lymphoma and CD30+ PTCL. AFM13: bispecific innate cell engager (antibody) binding CD30 on tumor cells and CD16A (FcγRIIIa) on NK cells to bridge NKs to targets and trigger ADCC and cytokine release. AB‑101: off‑the‑shelf allogeneic NK cell therapy providing cytotoxic effectors, killing is enhanced via CD16A engagement. Cyclophosphamide/fludarabine deplete host lymphocytes to aid NK engraftment, IL‑2 supports NK activation/expansion. Targets/pathways: CD30+ malignant cells, NK cell CD16A–mediated ADCC/innate cytotoxicity.